Lonneke ML, de Lau MMB. The epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–35.

Article  Google Scholar 

Yan R, Cai H, Cui Y, et al. Zonisamide: in Parkinson’s disease. CNS Drugs. 2009;23:703–11.

Article  Google Scholar 

Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018. https://doi.org/10.1101/CSHPERSPECT.A033118.

Article  PubMed  PubMed Central  Google Scholar 

Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583–90.

Article  PubMed  Google Scholar 

Liu Y, Zhang Y, Zhu K, Chi S, Wang C, Xie A. Emerging role of sirtuin 2 in Parkinson’s Disease. Front Aging Neurosci. 2019. https://doi.org/10.3389/FNAGI.2019.00372.

Article  PubMed  PubMed Central  Google Scholar 

Greenamyre JT, Hastings TG. Biomedicine. Parkinson’s: divergent causes, convergent mechanisms. Science. 2004;304:1120–2.

Wolters EC. Non-motor extranigral signs and symptoms in Parkinson’s disease. Park Relat Disord. 2009;15:S6-12.

Article  Google Scholar 

Boland DF, Stacy M. The economic and quality of life burden associated with Parkinson’s disease: a focus on symptoms. Am J Manag Care. 2012;18:168–75.

Google Scholar 

Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging. 2010;5:229–38.

CAS  PubMed  PubMed Central  Google Scholar 

Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol. 2015;132:96–168.

Article  CAS  PubMed  Google Scholar 

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33:1248–66.

Article  CAS  PubMed  Google Scholar 

NICE. Overview: Parkinson’s disease in adults: guidance. https://www.nice.org.uk/guidance/NG71. Accessed 27 Mar 2022.

Kong L, Xi J, Jiang Z, Yu X, Liu H, Wang Z. Zonisamide’s efficacy and safety on Parkinson’s Disease and dementia with lewy bodies: a meta-analysis and systematic review. Biomed Res Int. 2022;2022:4817488.

Article  PubMed  PubMed Central  Google Scholar 

Sharaf J, Williams K-AD, Tariq M, et al. The efficacy of safinamide in the management of Parkinson’s Disease: a systematic review. Cureus. 2022;14:e29118.

PubMed  PubMed Central  Google Scholar 

Matsunaga S, Kishi T, Iwata N. Combination therapy with zonisamide and antiparkinson drugs for Parkinson’s disease: a meta-analysis. J Alzheimer’s Dis. 2017;56:1229–39.

Article  CAS  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV, editors. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). 2022. www.training.cochrane.org/handbook. Accessed 27 Mar 2023.

Page MJ, McKenzie JE, Bossuyt PM, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020. https://doi.org/10.1136/BMJ.N71.

Article  PubMed  Google Scholar 

Higgins JPT, Savovi J, Page MJ, Elbers RG, SterneJAC. Chapter 8: Assessing risk of bias in a randomized trial. Available from: https://training.cochrane.org/handbook/current/chapter-08. Accessed 27 Mar 2022.

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.

Article  PubMed  Google Scholar 

Ioannidis JPA, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007;176:1091–6.

Article  PubMed  PubMed Central  Google Scholar 

Murata M, Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, et al. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: a phase 3 randomized clinical trial. Park Relat Disord. 2020;76:91–7.

Article  Google Scholar 

Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68:45–50.

Article  CAS  PubMed  Google Scholar 

Murata M, Hasegawa K, Kanazawa I, et al. Zonisamide improves wearing-off in Parkinson’s disease: a randomized, double-blind study. Mov Disord. 2015;30:1343–50.

Article  CAS  PubMed  Google Scholar 

Murata M, Hasegawa K, Kanazawa I, et al. Randomized placebo-controlled trial of zonisamide in patients with Parkinson’s disease. Neurol Clin Neurosci. 2016;4:10–5.

Article  CAS  Google Scholar 

Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology. 2018;90:e664–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pillai K, Bhat P, Kumar A, Rajan R, Bhushan M, Vishnu, et al. Zonisamide add-on in tremor-dominant Parkinson’ s disease: a randomized controlled clinical trial. Park Relat Disord. 2022;105:1–6.

Article  CAS  Google Scholar 

Stocchi F, Borgohain R, Onofrj M, Schapira AHV, Bhatt M, Lucini V, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord. 2012;27:106–12.

Article  CAS  PubMed  Google Scholar 

Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63:746–8.

Article  CAS  PubMed  Google Scholar 

Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial. JAMA Neurol. 2017;74:216–24.

Article  PubMed  Google Scholar 

Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled, phase II/III study. Park Relat Disord. 2020;75:17–23.

Article  Google Scholar 

Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29:1273–80.

Article  CAS  PubMed  Google Scholar 

Schapira AHV, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease. Eur J Neurol. 2013;20:271–80.

Article  CAS  PubMed  Google Scholar 

Wei Q, Tan Y, Xu P, et al. The XINDI Study: a randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson’s disease with motor fluctuations. CNS Drugs. 2022;36:1217–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kulisevsky J, Martinez-Horta S, Campolongo A, Pascual-Sedano B, Marin-Lahoz J, Bejr-kasem H, et al. A randomized clinical trial to evaluate the effects of safinamide on apathetic non-demented patients with Parkinson’s Disease. Front Neurol. 2022;13: 866502.

Article  PubMed  PubMed Central  Google Scholar 

Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29:229–37.

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov. Xadago report (2013): safinamide in early IPD , as add-on to dopamine agonist (MOTION). NCT00605683. Committee for Medicinal Products for Human Use (CHMP): p. 1–9

Müller T, Foley P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet. 2017;56:251–61.

Article  PubMed  Google Scholar 

Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term efficacy of safinamide on Parkinson’s Disease chronic pain. Adv Ther. 2018;35:515–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cattaneo C, Jost WH, Bonizzoni E. Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson’s disease patients. J Parkinsons Dis. 2020;10:89–97.

Article  PubMed  PubMed Central  Google Scholar 

Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C. Long-term effects of safinamide on mood fluctuations in Parkinson’s Disease. J Parkinsons Dis. 2017;7:629–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, Kosaka K, et al. Long-term efficacy and safety of zonisamide for treatment of parkinsonism in patients with dementia with lewy bodies: an open-label extension of a phase three randomized controlled trial. Am J Geriatr Psychiatry. 2022;30:314–28.

Article  PubMed  Google Scholar 

Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Kurtis MM. Impact of pharmacotherapy on quality of life in patients with Parkinson’s disease. CNS Drugs. 2015;29:397–413.

Article  CAS  PubMed  Google Scholar 

Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol. 2015;22:1184–91.